We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Jakavi

News List

Novartis' Jakavi bests current therapy for GvHD pharmatimes
April 26, 2020
Results of the Phase III REACH2 study show that Novartis' Jakavi (ruxolitinib) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GvHD) compared to best available therapy (BAT).
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program worldpharmanews
April 08, 2020
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction ...
Novartis and Incyte to trial Jakavi for Covid-19 pharmaceutical-technology
April 06, 2020
Novartis, in alliance with Incyte, has announced plans to evaluate Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.
Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm pharmatimes
April 03, 2020
Novartis and Incyte are planning to launch a clinical study to test the potential of Jakavi (ruxolitinib) in patients with COVID-19 associated cytokine storm.